NBIX Neurocrine Biosciences Inc

Simplify Asset Management Inc. reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 21.2% in Q3, now holding 36,624 shares valued at $5.14 million. Despite this reduction and recent insider selling, institutional investors collectively own 92.59% of the stock. Analysts maintain a "Moderate Buy" rating with a consensus target price of $175.25, following the company's strong Q3 earnings beat.

Burney Co. significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 202.7% in Q3, now holding 28,825 shares valued at $4.05 million. Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $175.25, and institutional investors own 92.59% of the company's stock. The company recently reported strong Q3 earnings, surpassing revenue and EPS estimates.

Rice Hall James & Associates LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% in the third quarter of 2025, selling 8,917 shares. Despite this, Neurocrine posted a strong Q3 performance, exceeding EPS and revenue expectations. Analysts remain largely bullish on NBIX, with several firms raising price targets and a consensus "Moderate Buy" rating.

This article reports that a director at Neurocrine Biosciences sold shares of the company's stock valued at $269,167. This transaction represents an insider selling activity, which can sometimes be monitored by investors for insights into a company's prospects. Specific details regarding the director's identity or the number of shares sold are not provided in this snippet.

Swedbank AB increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.7% in Q3, now holding 547,329 shares valued at $76.83 million. Other institutional investors like JPMorgan Chase & Co. and Norges Bank also hold significant positions, contributing to 92.59% institutional ownership. Neurocrine Biosciences reported strong Q3 earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $175.25.

Brighton Jones LLC significantly increased its stake in Neurocrine Biosciences (NBIX) by 266.2% in Q3 2025, now holding 10,216 shares worth $1.43 million, despite NBIX shares facing headwinds from disappointing Phase 3 clinical trial results for valbenazine in dyskinetic cerebral palsy. Analysts maintain a 'Strong Buy' rating for NBIX, citing robust earnings despite the clinical setback and stock fluctuations.